Brief: Ipsen Confirms 2026 Guidance
23/04/2026 06:05
April 23 (Reuters) - Ipsen SA IPN.PA: CONFIRMS FULL-YEAR 2026 GUIDANCE Q1 2026 TOTAL SALES UP 22.6% AT CONSTANT EXCHANGE RATES, 17.0% AS REPORTED Q1 REVENUE EUR 1,074.9 MILLION Source text: ID:nGNEc5bCQM Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients